June 2015, Vol 4, No 3
The Increasingly Important Role of Pathology in Oncology Patient Care
We are pleased to offer this issue of Personalized Medicine in Oncology (PMO) to you, our reading community. Since the onset of the personalized medicine era, we have repeatedly heard about the importance of the multidisciplinary team to include physicians, nurses, pharmacists, pathologists, social workers, and patients. Of late, we have been intrigued by the growing role of the pathologist. This era of breakthroughs in genetic medicine has placed pathologists at the forefront, delivering essential diagnostic clinical data to help determine the best treatment options for patients. There has been much debate over the proposal by the FDA to regulate laboratory developed tests. In this issue of PMO, the Interview with the Innovators department features our exchange with Drs Klein and Pratt of the Association for Molecular Pathology about the implications of this proposal.
Also in this issue, Ms Tsui and Dr Reckamp contribute their paper entitled “Expanding Options for EGFR-Mutant Non–Small Cell Lung Cancer with Afatinib,” and we continue to explore the changing landscape of oncology care through the fascinating science behind oncogenic driver mutations and their implications for patient care. Drs Yeh and Bazhenova at the University of California, San Diego, present “BRAF Mutations: An Old Oncogene and a New Target in Non–Small Cell Lung Cancer”; and Drs Shatsky and Bazhenova present “The RET Oncogene in Non–Small Cell Lung Cancer: Review of the Current Literature and Directions for the Future.”
We are dedicated to providing in-depth articles of the most compelling research from the personalized medicine front for all of us involved in patient care. It is our hope this information assists you in providing the best care for your patients.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Genetic tumor profiling, immune profiling, and immunohistocompatibility expression profiling are performed routinely at Yale Cancer Center for patients diagnosed with cancer. The results are presented to the multidisciplinary Molecular Tumor Board, which meets weekly to make treatment decisions. The following case exemplifies a personalized medicine approach and was presented by [ Read More ]
ASCO Launches First-Ever Clinical Trial: Aims to Learn from Patients with Advanced Cancer Who Lack Standard Treatment Options
Five Leading Pharmaceutical Companies Will Support Innovative Study, Contribute Drugs The American Society of Clinical Oncology (ASCO) recently announced its first-ever clinical trial that will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect real-world data on clinical outcomes to help learn the best uses of [ Read More ]